Inside the Path to the First FDA-Approved Concussion Drug
Join Oxeia CEO Dr. Michael Wyand, board member and former NFL quarterback Alex Smith, and Co-Founder & Trauma Surgeon Dr. Vishal Bansal for a live investor webinar on OXE-103, the candidate Oxeia believes could become the first FDA-approved drug for concussion.
This is not your typical early-stage biotech investment. Here's why:
The safety work is done. Oxeia licensed over $100M of clinical data from Daiichi Sankyo (9 completed studies, 300+ patients dosed, 4 Phase 1 safety trials) and did not have to repeat it.
The FDA has already cleared Oxeia to advance. No additional safety studies are required before Phase 2b.
Phase 2a delivered an 85% responder rate vs. 33% on standard care alone. Phase 2b is designed and ready to begin.
The team has $9B in prior exits. These include Arena Pharmaceuticals' $6.7B Pfizer acquisition and Kythera Biopharmaceuticals' $2.1B Allergan acquisition.
Hear directly from the team as they share the path forward, what's next for the business, and answer questions live from the audience.
This Reg CF offering is made available through StartEngine Primary, LLC, member FINRA/SIPC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view the Offering Circular and Related Risks.
OXE103 is an investigational therapy subject to regulatory review and clinical development risk.